anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide the use of a taurolidine or taurultam solution for preventing or reducing metastatic growth.  &lt;P&gt;SOLUTION: Minimally invasive laparoscopic tests which are paid attention when used particularly in treating abdominal malignant diseases have an advantage that the metastatic growth of tumors is within a predetermined range. Treatments of malignant diseases cause disturbance and release of malignant cells, then the malignant cells migrate to other sites, attached thereto and develop metastasis when their growth is started, resulting in unfortunate results as expected. In minimally invasive laparoscopic tests using trocar, disturbance of tumors and contact of the trocar with tumor&#39;s peripheral tissues during their removal are inevitable. The taurolidine or taurultam is used particularly in preventing or reducing the metastatic growth of tumors following surgeries, particularly following the use of trocar during minimal invasive laparoscopic surgeries.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The invention provides medicine for curing non-alcoholic steatohepatitis and a preparation method thereof. The medicine is prepared from traditional Chinese medicine as raw materials, and the ingredients of the raw materials are mainly radix astragali, semen coicis, rhizoma alismatis, seaweed, dandelion, radix salviae miltiorrhizae, polygonum cuspidatum, hawthorn, radix bupleuri, folium nelumbinis and polygonum multiflorum. The medicine is prepared into a water-honeyed pill, namely a dampness-dispelling stasis-dispersing fat-fighting pill. The traditional Chinese medicine is selected according to three-method combination of clearing heat and dampness, activating blood and dissolving stasis, and soothing liver and strengthening spleen, and a prescription is formed according to a principle of dispelling dampness, removing stasis and strengthening spleen, so that the effects of removing fat, dropping enzyme and repairing damaged liver cells can be achieved. Animal acute toxicity tests and pharmacodynamic tests prove that the medicine has good safety, can obviously control blood fat and improve the fatty liver, and has an obvious effect of losing weight. The medicine is clinically applied, the basic cure rate is 57.5 percent, the total effective rate is 94.3 percent, and the curative effect is higher than that of national medicine &#39;simvastatin&#39; approved by the state and the current medicine for curing the fatty liver in China.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition which prevents or improves wrinkles.  &lt;P&gt;SOLUTION: The wrinkle-improving composition includes (A) astaxanthin and (B) a compound or an extract having a stabilizing effect on dermal matrix component. Drugs, agents for external application, or foods and drinks containing the wrinkle-improving composition are presented. Cosmetics including the wrinkle-improving composition containing (A) astaxanthin and (B) a compound or its extract having a stabilizing effect on dermal matrix component are provided. A method for improving wrinkles in which foods comprising the effective components are taken is provided.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
To prevent a human input error or input omission for an electronic medical chart by automatically recording user&#39;s vital data such as a blood pressure, pulse, and a body temperature in an electronic medical chart by a simple configuration.SOLUTION: When identification information of an information display unit 3 provided on a belt body of a belt 1 for recognition is read by a terminal device, vital data on a user of the belt 1 for recognition such as a blood pressure, a pulse rate, a body temperature, and a respiration frequency measured by a sensor unit 11 attached to the belt body is measured. The measured vital data is transmitted wirelessly by a transmission unit 12 and received by the terminal device. Furthermore, the vital data is transmitted to a computer, which is a recording device (electronic medical chart), and recorded by the computer in association with a reception date for each user. By this arrangement, it is no longer necessary for a nurse to measure the blood pressure, the pulse rate, the body temperature, etc. of a user by a sphygmomanometer, a clinical thermometer, etc. and fill in a memorandum unlike a conventional system.SELECTED DRAWING: Figure 4
An automated system of personalized drug dosing and distribution using a home smart drug dispenser is described. When using this system, the medical prescription is electronically sent to the back-end server. Here, a dosage schedule for the patient is created on the basis of a medical recommendation using a database of drug interactions. Subsequently, the pharmacy prepares for the patient a personalized dose of medication stored in a cassette containing at least one compartment. Medicines are dosed to the patient from this cassette via the home smart drug dispenser, while the use of medicines is verified by technical means and information about their use is sent to the doctor. This makes it possible to effectively measure patients&#39; adherence, which directly affects the method and length of the treatment.
The invention relates to novel compositions and to novel methods for the administration of compositions to a patient or to cells in vitro for the treatment of human disorders. In one embodiment, compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia and other blood disorders. In another embodiment, compositions contain an inducing agent and an anti-viral agent.  The inducing agent induces the expression of a cellular or viral product, such as viral thymidine kinase, increasing the sensitivity of proliferating cells to the anti-viral agent. Typical anti-viral agents include nucleoside analogs such as ganciclovir that inhibit viral replication. Methods involve administration of therapeutically effective amounts of the inducing agent with the anti-viral agent to destroy virus-infected cells. Viral infections that can be treated include infections by herpes viruses such as Kaposi&#39;s--associated herpes virus and Epstein-Barr virus, HIV infections and HTLV infections. These compositions and methods are particularly effective against episomal and latent infections in proliferating cells. The invention also relates to novel methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies such as viral-induced tumors, other forms of neoplasia and for expansion of cells for hematopoietic transplantation.
The present invention provides a compound formula of a fleabane preparation for treating cardiovascular and cerebrovascular diseases, and a preparation method and the application of the compound formula. The compound formula of the present invention is prepared from 1 to 99% of fleabane, 99 to 1% of red peony root and proper percent of auxiliary materials. Compared with the prior art, the compound formula of the present invention conforms to the principle that &#39;in order to treat wind, blood needs to be treated firstly; when the blood is unobstructed, the wind can be eliminated&#39;; a method for promoting blood circulation, removing blood stasis and dredging channels is adopted. The fleabane which is bitter and warm is used as a main material, and is used for removing blood stasis and dredging channels; the red peony root is bitter and slightly cold; when the red peony root is mixed with blood, the red peony root has the efficiency of cooling blood heat, expelling blood stasis, dredging channels, and treating blood heat stasis; the red peony root is matched with the main material to achieve the efficiency of promoting blood circulation, removing blood stasis, expelling blood stasis and dredging channels, and is used as an auxiliary material. The fleabane and the red peony root are mixed to be used to realize the functions of promoting blood circulation, removing blood stasis, dredging channels and activating collaterals. The compound formula of the present invention has the advantages of less consumption of medicines, special effect, direct action channels, no disadvantage of overheating or overcooling sensation, and obvious characteristic of medicine use. The safety and the availability of a product are ensured through reasonable feasible preparation technology, and thus, the compound formula of the present invention can be suitable for patients to use for a long time.
A preparation method for a traditional Chinese medicine used for the treatment of kidney and yin deficient type acute glomerulus nephritis, belongs to the technical field of traditional Chinese medicine preparation methods. Currently, amoxicillin is commonly used for the treatment of the kidney and yin deficient type acute glomerulonephritis, but a rash occasionally occurs, and nausea, epigastricdiscomfort, diarrhea, etc. may occur after oral administer of a large amount of the amoxicillin. The technical scheme of the method is that: soaking the following 33 kinds of Chinese medicine herbs: prepared rehmannia root, edible bird&#39;s nest, mulberry fruit, radix scrophulariae, asparagi radix, dendrobium, wolfberry, ligustrum lucidum, tortoiseshell, turtle shell, black sesame, black soybean, human milk, Chinese date, Chinese yam, wheat, pseudostellaria root, black-bone silky fowl, cabbage, longan aril, bighead atractylodes rhizome, white peony root, American ginseng, Chinese angelica, lotusseed, Radix Codonopsis, sharpleaf galangal fruit, radix astragali, polygonatum rhizome, japonica rice, dry ginger, jecur lutrae, and licorice in water, and then decocting with slow fire. The decoction is the traditional Chinese medicine used for the treatment of kidney and yin deficient type acute glomerulus nephritis. The traditional Chinese medicine has the advantage of short treatment course and high cure rate; and sovereign, minister, assistant and courier are just right, preventing the adverse reaction caused by using western medicine.
PURPOSE:To obtain a photocurable dental resin composition having fast curability, and giving photocured products essentially excellent in the water resistance, strength and hardness and substantially equal to thermally cured products. CONSTITUTION:This photocurable dental resin composition contains an acrylic/ methacrylic acid mixture ester of formula I [R&lt;1&gt;, R&lt;2&gt; are a (substituted) 2-12C aliphatic hydrocarbon; R&lt;3&gt; is O-CO-NH, NH-CO-O] as a polymerizable component. This ester is compound having an acryloyl group and a methacryloyl group in the molecule and further having a urethane bond. Since the ester is the acrylic/methacrylic acid mixture ester, the ester is excellent in photocurability and gives cured products highly excellent in strength and hardness when cured with visible light. The ester of formula I wherein R&lt;3&gt; is O-CO-NH can easily be shnthesized e.g. by the urethane-forming reaction of an NCO-having acrylic or methacrylic acid with an OH-having methacrylic or an acrylic acid ester.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a hesperidin composition in which the characteristic smell of an enzyme-treated hesperidin is remarkably reduced.  &lt;P&gt;SOLUTION: This low smelling enzyme-treated hesperidin composition is obtained by allowing cyclodextrin glucanotransferase to act on a hesperidin-containing product extracted from lemon in the presence of a glucose-imparting agent, and further treating the product with one or more of porous synthetic adsorbing resins, ion exchange resins, and carbon. A method for producing the composition and a drink or food, a cosmetic or a medicine containing the composition are disclosed. The hesperidin-containing product is slurry, and it is preferable that the hesperidin-containing product is heated at a temperature of 75 to 100°C for 15 to 60 minutes under the ordinary pressure prior to an enzymatic treatment. It is preferable that the low smelling enzyme-treated hesperidin composition is either of an additive for foods, an additive for cosmetics, and an additive for medicines.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the subject inhibitor capable of restraining osteoclast from absorbing a bone component and useful for treatment and prophylaxis of bone loss diseases e.g. osteoporosis by including a specific indole derivative as an active ingredient. SOLUTION: This inhibitor comprises a compound of formula I [R&lt;1&gt; and R&lt;3&gt; are each a hydrocarbon; R&lt;2&gt; is H or a (substituted) hydrocarbon; and (n) is 0 to 4], pref., a compound of formula II as an active ingredient. The inhibitor as a drum may be conventionally formed into preparations in the form of e.g. an encapsulated agent, powder agent, granular agent or pill and these preparations may be administrated orally or non-orally. Generally it is preferable to administer a dose of about 1.0 to 1,000 mg to an adult a day by dividing the dose into one to several portions. The objective inhibitor comprising a compound of formula II as an active ingredient is esp. small in cytotoxicity and useful as a prophylactic or therapeutic agent for osteoporosis.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a curative medicine for undesirable skin states, a curative medicine for tumorous diseases, and a method for identifying a compound for repressing lymphatic endothelial cell growth dependent on a hepatocyte growth factor.  &lt;P&gt;SOLUTION: A composition for regulating the activity of a hepatocyte growth factor is used to regulate the generation and function of a lymphatic channel. As a hepatocyte growth factor active agonist, a hepatocyte growth factor polypeptide and a nucleic acid for coding its analog are exemplified. For treating tumorous diseases, a hepatocyte growth factor active antagonist is used. More specifically, an α 9 integrin active antagonist is used.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To obtain a hair-dyeing composition of high safety and stability, showing good applicability such as high spreadability and coatability despite of no sagging of the hair dye during dyeing treatment and without dyeing speck, comprising a specific saccharide derivative and an oxidation coloring agent. CONSTITUTION:This oxidation hair-dyeing agent composition comprises the combination of a saccharide derivative of formula I (A is a residue after exclusion of (n)XOH groups from the saccharide; (n) is &gt;=1) with an oxidation coloring agent. As the saccharide derivative, that of formula I to be a branched aliphatic glycoside of formula II (A is a residue after exclusion of hemiacetal hydroxy groups from the saccharide, or a saccharide branched aliphatic ether of formula III (A is a residue after exclusion of (n)Xnon-hemiacetal OH groups from the saccharide) is particularly preferred. Particularly, iso-stearly maltoside and maltitol isostrearly ether are preferred. It is preferred that an oxidizing agent is added to these compositions. Particularly, a composition obtained by mixing the first agent containing the saccharide derivative and an oxidation coloring agent simultaneously with the second agent containing the oxidizing agent is preferred.
Quinolones with antihypertensive activity have the general formula I, &lt;IMAGE&gt; I  wherein X is the residue of an optionally substituted benzene ring; R is lower alkyl; R3 is hydrogen or lower alkyl; R1 and R2, which may be the same or different, are hydrogen, lower alkyl, or, together with the nitrogen atom to which they are attached, form a 5 to 7 membered saturated heterocyclic ring optionally containing an additional hetero atom selected from nitrogen, oxygen and sulphur and optionally substituted by 1 or more lower alkyl groups; and the dotted line between positions 2 and 3 of the quinolone nucleus represents an optional bond. The compounds are useful as antihypertensive agents. They are also indicated for use in treating heart failure and ischaemic heart disease. With the exception of the three compounds 1-methyl-4-oxo-1,4-dihydroquinoline-3-sulphonamide, 1,N-dimethyl-4-oxo-1,4-dihydroquinoline-3-sulphonamide and 6,7-dimethoxyl-methyl-4-oxo-1,4-dihydroquinoline-3-sulphonamide, the quinolones of formula I are novel. Pharmaceutical compositions containing the compounds of formula I are described. Processes for preparing the novel quinolones are also described.
Transfection particles for delivery of nucleic acid into higher eucaryotic cells in vitro and in vivo comprises one or more nucleic acid molecules condensed by organic cationic molecules. The discrete and stable particles are obtained by complexing the nucleic acid molecules with identical or different organic cationic precursor molecules without crosslinking nucleic acid molecules, and covalently linking the precursor molecules to each other on the nucleic acid template. For specific cellular targeting, the particles may carry targeting molecules, e.g. sugars. Preferred cationic precursor molecules are lipophilic detergents that are linked to form lipids. The particles contain preferably only one nucleic acid molecule which makes them useful for gene therapy and for delivery of large DNA molecules. &lt;IMAGE&gt;
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for cultivating Lyphyllum decastes enabling increase of yield.  &lt;P&gt;SOLUTION: This method for cultivating Lyphyllum decastes comprises using a waste bed of Grifola frondosa mushroom bed cultivation as a medium base material. It is suitable to further use as the base material rice bran and/or bran and to use the waste bed through accumulating the waste bed for at least 6 months. The deposit numbers of the Lyphyllum decastes strain are FERM P-19498 and FERM P-19499. A skin disease dermatosis retarder and a high blood pressure retarder each containing the dry product or the extract of the Lyphyllum decastes strain are also provided.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The invention relates to a recipe and a method for treating incorporative small intestinal channel and stomach channel diseases by traditional Chinese medicine. The medicine recipe comprises 3g of fistular onion stalk, 3g of bamboo leaf, 3g of scutellaria baicalensis, 3g of folium isatidis, 3g of oldenlandia diffusa, 3g of bupleurum falcatum, 1g of rheum officinale, 3g of croton, 2g of silkworm excrement, 2g of loofah sponge, 2g of alpinia katsumadai, 2g of spora lygodii, 2g of bixie, 2g of long pepper, 3g of pericarpium arecae, 2g of gizzard pepsin, 2g of pseudo-ginseng, 2g of cowherb seed, 2g of rhizoma acori graminei 2g of Chinese date, 3g of radix glehniae and 3g of asparagus fern. Acupuncture points of da ying, shimonoseki, cheek crevice, qishe, t&#39;ien jung, warehouse, quyuan, ju chung, tai yi, tiao kou, yanglao, houxi and neiting are selected. Auxiliary appliances comprise a foreign matter discharge barrel, a medicine guide-in barrel, an auxiliary barrel, an ozone generator, a foreign matter discharge ultrasonic generator and the like. Auxiliary articles comprise purified water, the fistular onion stalk and limonite. The recipe and the method can cure incorporative small intestinal channel and stomach channel diseases and can be used in clinical application.
NEW MATERIAL:A benzimidazole derivative of formula I (R1 is 4-6C alkyl; R2 is methyl). EXAMPLE:2-[2-(N-isobutyl-N-methylamino)benzylsulfinyl]benzimidazole. USE:Useful as an anti-ulcer agent. The compound of formula I has an excellent gastric acid secretion-inhibiting action based on a specific H&lt;+&gt;+K&lt;+&gt;ATPase- inhibiting action thereof and is employed in the preparation of oral or parenteral agents. PREPARATION:A 2-mercapto benzimidazole of formula II is subjected to a reaction a 2-aminobenzyl compound of formula III (R1 is 4-6C alkyl; R2 is methyl; X is a reactive group) preferably in the presence of an alkaline agent in an inactive solvent such as toluene at the room temperature to the reflux temperature of the solution to prepare a compound of formula IV. The compound of formula IV is oxidized with an oxidizing agent such as hydroperoxide in an inactive solvent at -30 deg.C to 50 deg.C to provide the compound of formula I.
NEW MATERIAL:A compound shown by the formula I (A is phenyl, or cyclohexyl; R&lt;1&gt; is H, or lower alkyl; X is H, or halogen), its salt, or lower alkyl ester. EXAPLE:4-Phenyldisulfanyl-3-chlorobenzene-alpha-methylacetic acid. USE:An anti-inflammatory agent. Having high lipoxygenase inhibitory action and cyclooxygenase inhibitory action, showing various pharmaceutical activities such as alleviation of thrombosis, asthma, allergy, improvement of arteriosclerosis, etc. as an anti-inflammatory of new type. PREPARATION:A compound shown by the formula II is reacted with thiophenol or cyclohexylmercaptan in the presence of an oxidizing agent (e.g. sulfoxide, etc.) at room temperature -100 deg.C, to give a compound shown by the formula I .
The present invention relates to compressed tablets for peroral deliveryof the cannabinoid [delta]9-tetrahydrocannabinol(THC).More particularly, the invention provides a compressed tablet having a tablet weight of 25-1000 mg, said tablet being composed of: compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment . 30-90 wt % of a granulate; . 10-70 wt % of lactose; and . 0-30wt % of other tablet excipients; wherein the granulate contains: a.2-5 wt % of [delta]9-tetrahydrocannabinol; b.2-20 wt % of sucrose fatty acid mono-ester; c.50-96 wt % of lactose; d.0.05-0.6 wt % of antioxidant; and e.0-25wt % of other granulate excipients. The compressed tablets according to the invention can conveniently be used in the treatment of spasticity and pain caused by multiple sclerosis, neurophatic pain, chronic pain, behavioral disturbance by Alzheimer&#39;s disease, stroke, spinal cord injury, peripheral neuropathy, neurogenic pain, nociceptive pain and nausea. The invention further provides a method for the manufacture of the compressed tablets.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a water retention sheet for the skin, which has excellent compatibility with the skin, firm feeling and moist feeling and is extremely suitable for beautification use, medical treatment use, etc., and to provide a method for producing the same.  &lt;P&gt;SOLUTION: The water retention sheet for the skin is a sheet that is applied in a water retention state to the skin and used. The sheet is obtained by forming a finely divided substance of insoluble collagen in a suspended state in water and coagulating the suspension in a hydrous state as it is and is used without drying. The insoluble collagen is mammal-derived collagen and has 35-50°C denaturation temperature. The water retention sheet has 3-8 wt.% of the collagen content. The water retention sheet is produced by a method comprising a process (a) for preparing a water suspension containing 3-8 wt.% of the finely divided substance of insoluble collagen and a process (b) for forming the water suspension into a sheet and coagulating it in a hydrous state as it is.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT